SCHEMBL30348325

SCHEMBL30348325

CN1CCC(CNc2ncc3c(-c4ccc5ncc(OC6CCN(C)CC6)nc5c4)c[nH]c3n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 1/20 0.44
▸ DYRK1A Q13627 3/20 0.41
▸ CLK2 P49760 1/20 0.41
▸ CLK3 P49761 1/20 0.41
▸ PIK3CD O00329 2/20 0.40
▸ PIK3CA P42336 2/20 0.40
▸ PIK3CG P48736 2/20 0.40
▸ PIK3CB P42338 1/20 0.40
▸ MET P08581 1/20 0.39
▸ DYRK1B Q9Y463 3/20 0.38
▸ USP30 Q70CQ3 1/20 0.37
▸ JAK3 P52333 4/20 0.37
▸ IL2 P60568 1/20 0.37
▸ MAP4K1 Q92918 1/20 0.37
▸ EGLN1 Q9GZT9 1/20 0.36
▸ BRD4 O60885 2/20 0.36
▸ TNIK Q9UKE5 1/20 0.36
▸ PDPK1 O15530 1/20 0.36
▸ VNN1 O95497 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25158081 1.00 TDO2 (0.44) TDO2DYRK1ACLK2CLK3PIK3CD
SCHEMBL30347974 0.94 TDO2 (0.42) TDO2DYRK1ACLK2CLK3PIK3CD
SCHEMBL25225695 0.94 TDO2 (0.42) TDO2DYRK1ACLK2CLK3PIK3CD
SCHEMBL30347968 0.92 TDO2 (0.45) TDO2DYRK1ACLK2CLK3PIK3CD
SCHEMBL25520039 0.92 TDO2 (0.45) TDO2DYRK1ACLK2CLK3PIK3CD
SCHEMBL30348159 0.89 TDO2 (0.43) TDO2DYRK1ACLK2CLK3PIK3CD
SCHEMBL25158507 0.89 TDO2 (0.43) TDO2DYRK1ACLK2CLK3PIK3CD
SCHEMBL25520047 0.89 TDO2 (0.43) TDO2DYRK1ACLK2CLK3PIK3CD
SCHEMBL30347703 0.89 TDO2 (0.43) TDO2DYRK1ACLK2CLK3PIK3CD
SCHEMBL25192962 0.89 TDO2 (0.47) TDO2DYRK1ACLK2CLK3PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 TDO2 539/4885DYRK1A 1/4885CLK2 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback